The Oxen Group is liking a bearish market or at least a somewhat sideways market. The market has jumped up for three straight days, and a technical pullback with investors taking profits may be in order. One area that appears fundamentally bearish is the housing sector. Ultrashort Proshares Real Estate (SRS), which is a housing/commercial real estate ETF, looks to be bearish on a general market trend as well as news that foreclosures are continuing to rise to now 15% for the year and 33% in June.
The trend is not stabilizing, which while not directly affecting commercial real estate means that commercial real estate is in a tough spot, as well. Futures are currently registering in the red, and we did not have any large market moving earnings or news come out in after hours. Further, news that CIT Group has failed to get lending and will be filing bankruptcy shows that the recession may still be taking more victims. Many earnings are coming out in the morning, but not a marquis name that could really drive the market higher except perhaps JPMorganChase. Economic data being released could further influence a pullback if jobless claims come in under expectations. Even if jobless claims are good and JPMorgan is solid, investors will be looking to sell these stocks into this upward trend. SRS, however, is in the exact opposite boat. The ETF is extremely undervalued, just passed under a lower bollinger band, and is way oversold. Therefore, it is setting up for a perfect buying opportunity.
Entry: Recommend buying in 15-30 minutes into session. Exit: We recommend exiting after a 2-5% increase. Stop Loss: We recommend a 3% stop loss on all buy in prices Upper Resistance: 21.00
The Oxen Group, for Wednesday, is looking at a continued bearish market for a third straight day. With today’s bullish economic data, investors still sold off stocks, pointing to a bear market that should continue as a bland day continues tomorrow. Most analysts think that Obama’s financial regulation plans will not do much for the market. Futures are up, in after hours, but with this data, if a rally cannot be held, then there is no reason to expect a positive day at this time. The CPI will determine the day.
One industry that really looks bearish tomorrow is housing. The housing industry got a shot with, on the surface, bullish news. Instead, the housing market ended up with minimal gains or in the red. Light volume shows that investors are not excited about the market.
Tomorrow should continue a downward trend for housing sparked by a downgrade of Beazer Homes to ultra-junk status by the S&P. That sent the stock down 10% in after hours. This is really a market that needs some very bullish jolt to get it going, and it until that happens this market is fundamentally bearish. With that said, Ultrashort Proshares Real Estate looks to be a strong play as an inverse to the housing industry, which should fall after its run up today. Technically, the ETF has been moving and is trending upwards with more buyers getting involved. Buyers are still on the sidelines to short housing. Buy in early and watch the run!
Entry: Recommend buying within first 5 – 25 minutes. Exit: We recommend exiting after a 2-4% increase. Upper Resistance: 22.50
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at email@example.com with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
A large call spread initiated on Orexigen Therapeutics, Inc. (Ticker: OREX) on Monday morning looks for shares in the name to rally approximately 30% by September expiration. The September expiration is noteworthy as the company awaits the results of the FDA’s review of its resubmitted New Drug Application (NDA) for NB32, an investigational medication being evaluated for weight loss, after the review was extended for three months back in June. The upcoming Prescription Drug User Fee Act (PDUFA) date is September 11, 2014, according to a press release issued by the company. Shares in Orexigen today are up roughly 0.40% at $5.34 as of 2:15 p.m. ET.
As Turkey's graft probe continues (which the Prime Minister believes is a conspiracy - fact or not - created by The West), AP reports that Recep Tayyip Erdogan has said he no longer holds "direct" telephone conversations with U.S. President Barack Obama, suggesting a rift between the leaders who were once close. What is perhaps even more concerning is Turkey's recent de-dollarization discussions with Russia to move to settlement in local currencies. It appears 'allies' are falling by the way-side quicker than many thought...
The July Consumer Price Index for Urban Consumers (CPI-U) released this morning puts the June year-over-year inflation rate at 2.07%, fractionally off last month's 2.13% 19-month high, but well below the 3.88% average since the end of the Second World War and 13% below its 10-year moving average.
For a comparison of headline inflation with core inflation, which is based on the CPI excluding food and energy, see this monthly feature.
For better understanding of how CPI is measured and how it impacts your household, see my Inside Look at CPI components.
For an even closer look at how the components are behaving, see this X-Ray View of the data for the past six months.
The Bureau of Labor Statistics (BLS) has compiled...
Despite a highly eventful week in the news, not much has changed from a stock market perspective. No doubt, investors have grown immune to the daily reports of geopolitical turmoil, including Ukraine vs. Russia for control of the eastern regions, Japan’s dispute with China over territorial waters, Sunni vs. Shiite for control of Iraq, Christians being driven out by Islamists, and other religious conflicts in places like Nigeria and Central African Republic. But last Thursday’s news of the Malaysian airliner tragically getting shot down over Ukraine, coupled with Israel’s ground incursion into Gaza, had the makings of a potential Black Swan event, which in my view is the only thing that could derail the relentless bull march higher in stocks.
Nevertheless, when it became clear that the airline...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
We tried holding up stock prices but couldn’t get the job done. Market Shadows’ Virtual Value Portfolio dipped by 2% during the week but still holds on to a market-beating 8.45% gain YTD. There was no escaping the downdraft after a major Portuguese bank failed. Of all the triggers for a large selloff, I’d guess the Portuguese bank failure was pretty far down most people's list of "things to worry about."
All three major indices gave up some ground with the Nasdaq composite taking the hardest hi...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
I just wanted to be sure you saw this. There’s a ‘live’ training webinar this Thursday, March 27th at Noon or 9:00 pm ET.
If GOOGLE, the NSA, and Steve Jobs all got together in a room with the task of building a tremendously accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.
Well, I hate to break it to you though… they never got around to building it, but my friends at Market Tamer did.
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.